Oncotelic Therapeutics' Partner TechForce Robotics Advances Automation with Phase 2 Robot Deployment at SAPU Bio
OTLC has more than doubled off its 52-week low of $0.015.
Summary
Oncotelic Therapeutics' partner, TechForce Robotics, has completed Phase 2 deployment of its PUR-E autonomous clean room support robot at Oncotelic's SAPU Bio OEB-5 sterile injectable cGMP facility. This advancement expands the automation initiative into sterile manufacturing operations, following the initial Phase 1 deployment of the LIM-E robot. This operational progress demonstrates execution on the joint development partnership announced in April, which aims to integrate robotics and AI into high-containment pharmaceutical manufacturing. For a company that recently reported a "going concern" warning in its Q1 2026 10-Q, this tangible step forward in a strategic initiative provides a positive operational update.
At the time of this announcement, OTLC was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $18.3M. The 52-week trading range was $0.02 to $0.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.